Cargando…
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell lung cancer (NSCLC) and resulted in the drug’s approval for this indication. A cohort that included neoadjuvant and adjuvan...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232990/ https://www.ncbi.nlm.nih.gov/pubmed/37274265 http://dx.doi.org/10.3389/fonc.2023.1178313 |
_version_ | 1785052128841039872 |
---|---|
author | Goldman, Jonathan W. Sholl, Lynette M. Dacic, Sanja Fishbein, Michael C. Murciano-Goroff, Yonina R. Rajaram, Ravi Szymczak, Sylwia Szpurka, Anna M. Chao, Bo H. Drilon, Alexander |
author_facet | Goldman, Jonathan W. Sholl, Lynette M. Dacic, Sanja Fishbein, Michael C. Murciano-Goroff, Yonina R. Rajaram, Ravi Szymczak, Sylwia Szpurka, Anna M. Chao, Bo H. Drilon, Alexander |
author_sort | Goldman, Jonathan W. |
collection | PubMed |
description | The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell lung cancer (NSCLC) and resulted in the drug’s approval for this indication. A cohort that included neoadjuvant and adjuvant selpercatinib was opened on LIBRETTO-001 for early-stage RET fusion-positive NSCLC with the primary endpoint of major pathologic response. A patient with a stage IB (cT2aN0M0) KIF5B-RET fusion-positive NSCLC received 8 weeks of neoadjuvant selpercatinib at 160 mg twice daily followed by surgery. While moderate regression in the primary tumor (stable disease, Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1) was observed radiologically, assessment via an Independent Pathologic Review Committee revealed a pathologic complete response (0% viable tumor). This consensus assessment by three independent pathologists was aided by RET fluorescence in situ hybridization testing of a reactive pneumocyte proliferation showing no rearrangement. Neoadjuvant selpercatinib was well-tolerated with only low-grade treatment-emergent adverse events. The activity of prospective preoperative selpercatinib in this case establishes proof of concept of the potential utility of RET inhibitor therapy in early-stage RET fusion-positive NSCLC. |
format | Online Article Text |
id | pubmed-10232990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102329902023-06-02 Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer Goldman, Jonathan W. Sholl, Lynette M. Dacic, Sanja Fishbein, Michael C. Murciano-Goroff, Yonina R. Rajaram, Ravi Szymczak, Sylwia Szpurka, Anna M. Chao, Bo H. Drilon, Alexander Front Oncol Oncology The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell lung cancer (NSCLC) and resulted in the drug’s approval for this indication. A cohort that included neoadjuvant and adjuvant selpercatinib was opened on LIBRETTO-001 for early-stage RET fusion-positive NSCLC with the primary endpoint of major pathologic response. A patient with a stage IB (cT2aN0M0) KIF5B-RET fusion-positive NSCLC received 8 weeks of neoadjuvant selpercatinib at 160 mg twice daily followed by surgery. While moderate regression in the primary tumor (stable disease, Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1) was observed radiologically, assessment via an Independent Pathologic Review Committee revealed a pathologic complete response (0% viable tumor). This consensus assessment by three independent pathologists was aided by RET fluorescence in situ hybridization testing of a reactive pneumocyte proliferation showing no rearrangement. Neoadjuvant selpercatinib was well-tolerated with only low-grade treatment-emergent adverse events. The activity of prospective preoperative selpercatinib in this case establishes proof of concept of the potential utility of RET inhibitor therapy in early-stage RET fusion-positive NSCLC. Frontiers Media S.A. 2023-05-18 /pmc/articles/PMC10232990/ /pubmed/37274265 http://dx.doi.org/10.3389/fonc.2023.1178313 Text en Copyright © 2023 Goldman, Sholl, Dacic, Fishbein, Murciano-Goroff, Rajaram, Szymczak, Szpurka, Chao and Drilon https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Goldman, Jonathan W. Sholl, Lynette M. Dacic, Sanja Fishbein, Michael C. Murciano-Goroff, Yonina R. Rajaram, Ravi Szymczak, Sylwia Szpurka, Anna M. Chao, Bo H. Drilon, Alexander Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer |
title | Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer |
title_full | Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer |
title_fullStr | Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer |
title_full_unstemmed | Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer |
title_short | Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer |
title_sort | case report: complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage ret fusion-positive non-small cell lung cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232990/ https://www.ncbi.nlm.nih.gov/pubmed/37274265 http://dx.doi.org/10.3389/fonc.2023.1178313 |
work_keys_str_mv | AT goldmanjonathanw casereportcompletepathologicresponsetoneoadjuvantselpercatinibinapatientwithresectableearlystageretfusionpositivenonsmallcelllungcancer AT sholllynettem casereportcompletepathologicresponsetoneoadjuvantselpercatinibinapatientwithresectableearlystageretfusionpositivenonsmallcelllungcancer AT dacicsanja casereportcompletepathologicresponsetoneoadjuvantselpercatinibinapatientwithresectableearlystageretfusionpositivenonsmallcelllungcancer AT fishbeinmichaelc casereportcompletepathologicresponsetoneoadjuvantselpercatinibinapatientwithresectableearlystageretfusionpositivenonsmallcelllungcancer AT murcianogoroffyoninar casereportcompletepathologicresponsetoneoadjuvantselpercatinibinapatientwithresectableearlystageretfusionpositivenonsmallcelllungcancer AT rajaramravi casereportcompletepathologicresponsetoneoadjuvantselpercatinibinapatientwithresectableearlystageretfusionpositivenonsmallcelllungcancer AT szymczaksylwia casereportcompletepathologicresponsetoneoadjuvantselpercatinibinapatientwithresectableearlystageretfusionpositivenonsmallcelllungcancer AT szpurkaannam casereportcompletepathologicresponsetoneoadjuvantselpercatinibinapatientwithresectableearlystageretfusionpositivenonsmallcelllungcancer AT chaoboh casereportcompletepathologicresponsetoneoadjuvantselpercatinibinapatientwithresectableearlystageretfusionpositivenonsmallcelllungcancer AT drilonalexander casereportcompletepathologicresponsetoneoadjuvantselpercatinibinapatientwithresectableearlystageretfusionpositivenonsmallcelllungcancer |